Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan to Quadruple Supplies of Sublingual Hay Fever Therapy in 5 Years
May 31, 2023
- LDP OKs Project Team Proposal to Boost Pharma Innovation, Create Command Tower
May 31, 2023
- LDP Launches Lawmakers’ League on Self-Medication
May 31, 2023
- Japan to Launch New Forum to Spur Secondary Use of Medical Data in Drug Discovery
May 30, 2023
- MOF Panel Flags Japan’s High Drug Cost per Capita, Stays Pat on Cost-Effectiveness-Based Reimbursement, Copay Review
May 30, 2023
- Cancer Meds from Servier, Taiho, Pfizer’s AA Drug Clear Review for June Approval
May 30, 2023
- PM Advisors Make Irregular Call for Properly Rewarding Innovation to Boost Japan’s Drug Discovery Capabilities
May 29, 2023
- Gene Therapy Luxturna Now in Line for Approval in June
May 29, 2023
- Relief Claims OK’ed for 14 More Deaths Possibly Tied to COVID Jabs
May 29, 2023
- Japan Approves Label Expansions for Ultomiris, Skyrizi, Vanflyta
May 26, 2023
- Expert Panel Meeting Canceled Due to Lack of Coordination: MHLW Official
May 26, 2023
- Expedite Introduction of High-Priority Vaccines into National Schedule: Trade Groups
May 25, 2023
- Orphan Tag Granted to Opdivo, Leniolisib, and 6 More APIs
May 24, 2023
- LDP Pharma Study Group Proposes Removing Cap for Social Security Costs
May 23, 2023
- Ophthalmic Mitomycin, OD Tablets for Takecab and Tarlige to Get Listing on May 24
May 23, 2023
- MHLW Cancels Expert Panel Meeting on May 23, Report Delayed
May 23, 2023
- Ferring’s Oral Budesonide for UC Treatment Up for Advisor Review on June 2
May 22, 2023
- PMDA Reviewing Safety Risks for Opdivo, Yervoy
May 22, 2023
- Novo Mum over Pass on Wegovy Listing in May
May 19, 2023
- Japan Eyes Pilot Program for OTC-Switching of Emergency Contraceptives, Public Commenters Overwhelmingly Positive
May 18, 2023
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…